Alicia Morgans, MD, discusses ARACOG findings on cognitive outcomes with darolutamide vs enzalutamide and the influence of genetic dementia risk.
|Videos|December 15, 2021
Dr. Pettaway: 2021 recipient of SUO’s Huggins Medal
Author(s)Urology Times staff
“I believe that this is, of course,…a harbinger of what is to come—those of underserved backgrounds being…featured [more] in our organizations,” says Curtis A. Pettaway, MD.
Advertisement
In this video, Curtis A. Pettaway, MD, discusses what receiving the Society of Urologic Oncology’s 2021 Huggins Medal meant to him. Pettaway is a professor of urology at the University of Texas MD Anderson Cancer Center in Houston.
Advertisement
Related to this article
Elie Kaplan-Marans, MD, discusses geographic disparities in reproductive urology access and how work force gaps may affect comprehensive infertility evaluations.
Tamim Niazi, MDCM, reviews DASL-HiCaP findings showing improved metastasis-free survival with darolutamide added to ADT and radiation therapy.
Alicia K. Morgans, MD, MPH, reviews promising prostate cancer findings from ESMO 2026,
Alberto Briganti, MD, PhD, discusses results from the PROTEUS substudy, evaluating perioperative apalutamide plus ADT vs surgery alone in high-risk localized or locally advanced prostate cancer.
Andrea Necchi, MD, discusses how results from the CA017-078 trials compares with other perioperative immunotherapy trials in muscle-invasive bladder cancer.
Daniel Heng, MD, discusses final LITESPARK-011 results, including sustained PFS benefit with belzutifan plus lenvatinib vs cabozantinib in advanced ccRCC.
Carlos A. Vargas, MD, discusses updated survival outcomes, safety, and the mechanism of SYNC-T SV-102, an investigational in situ immunotherapy for metastatic prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
UGN-501 enters phase 1 testing for recurrent non–muscle invasive bladder cancer
2
Infertility care: Examining geographic gaps in access
3
ESMO 2026 On Location - Why pCR is not the whole story in cisplatin-ineligible MIBC
4
Alicia Morgans, MD, discusses cognitive outcomes with darolutamide vs enzalutamide
5